BALDWIN PARK, Calif., Dec. 19, 2024 /PRNewswire/ -- StemCyte announced a significant breakthrough in its Phase IIa clinical trial of HPC, Cord Blood (HPC, CB) for treating Post-COVID Syndrome (Long COVID). This trial results demonstrated that cord blood significantly improved fatigue...
Hence then, the article about stemcyte announces successful phase iia clinical trial results for hpc cord blood in treating post covid syndrome 85 of patients experience complete relief from fatigue symptoms was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms )
Also on site :
- Nigerian general killed in Islamic State attack
- The Oil Shock Is Worse Than You Think
- Kremlin explains Easter ceasefire